TY - JOUR AU - Molica, S. PY - 2017 DA - 2017// TI - Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future JO - Expert Rev Hematol VL - 10 UR - https://doi.org/10.1080/17474086.2017.1313108 DO - 10.1080/17474086.2017.1313108 ID - Molica2017 ER - TY - JOUR AU - Byrd, J. C. AU - Brown, J. R. AU - O'Brien, S. PY - 2014 DA - 2014// TI - Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1400376 DO - 10.1056/NEJMoa1400376 ID - Byrd2014 ER - TY - STD TI - Byrd JC, Hillmen P, O'Brien SM, et al. Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study. J Clin Oncol. 2017;35:(suppl; abstr 7510) ID - ref3 ER - TY - JOUR AU - Zelenetz, A. D. PY - 2017 DA - 2017// TI - Chronic lymphocytic leukemia: individualizing treatment approach JO - J Natl Compr Canc Netw VL - 15 UR - https://doi.org/10.6004/jnccn.2017.0081 DO - 10.6004/jnccn.2017.0081 ID - Zelenetz2017 ER - TY - JOUR AU - Mato, A. R. AU - Hill, B. T. AU - Lamanna, N. PY - 2017 DA - 2017// TI - Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients JO - Ann Oncol VL - 28 UR - https://doi.org/10.1245/s10434-016-5649-6 DO - 10.1245/s10434-016-5649-6 ID - Mato2017 ER - TY - JOUR AU - Burger, J. A. AU - Keating, M. J. AU - Wierda, W. G. PY - 2014 DA - 2014// TI - Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70335-3 DO - 10.1016/S1470-2045(14)70335-3 ID - Burger2014 ER - TY - JOUR AU - Jain, P. AU - Keating, M. J. AU - Wierda, W. G. PY - 2017 DA - 2017// TI - Long-term follow-up of treatment with ibrutinib and rituximab in patients with high-risk chronic lymphocytic leukemia JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-1948 DO - 10.1158/1078-0432.CCR-16-1948 ID - Jain2017 ER - TY - JOUR AU - Sharman, J. P. AU - Farber, C. M. AU - Mahadevan, D. PY - 2017 DA - 2017// TI - Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial JO - Br J Haematol VL - 176 UR - https://doi.org/10.1111/bjh.14447 DO - 10.1111/bjh.14447 ID - Sharman2017 ER - TY - STD TI - Sharman JP, Brander DM, Mato AR, et al. Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study. J Clin Oncol. 2017;35:(suppl; abstr 7504). ID - ref9 ER - TY - JOUR AU - Fraietta, J. A. AU - Schwab, R. D. AU - Maus, M. V. PY - 2016 DA - 2016// TI - Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells JO - Semin Oncol VL - 43 UR - https://doi.org/10.1053/j.seminoncol.2016.02.006 DO - 10.1053/j.seminoncol.2016.02.006 ID - Fraietta2016 ER - TY - STD TI - Gill S, Frey NV, Hexner EO, et al. CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL. J Clin Oncol. 2017;35:(suppl; abstr 7509). ID - ref11 ER -